
GENB Stock Forecast & Price Target
GENB Analyst Ratings
Bulls say
Generate Biomedicines is poised for success due to its innovative approach to drug discovery through AI, a strong pipeline of promising candidates including a twice-yearly dosing drug for severe asthma, partnerships with reputable institutions and potential collaborations with major pharmaceutical companies, and a solid financial position with potential for significant milestones and royalties.
Bears say
Generate Biomedicines is heavily reliant on its AI-generated platform for drug discovery and development, but the platform has yet to produce a defining clinical success. Additionally, its lead product candidate, GB-0895, faces competition from an established, well-reimbursed standard of care for severe asthma, and there are concerns about potential supply chain disruptions from regulatory compliance changes. The company also has a high cash burn rate and may need to raise additional capital in the future to fund operations, which could pose a risk to its financial stability.
This aggregate rating is based on analysts' research of Generate Biomedicines Inc and is not a guaranteed prediction by Public.com or investment advice.
GENB Analyst Forecast & Price Prediction
Start investing in GENB
Order type
Buy in
Order amount
Est. shares
0 shares